Retrieve available abstracts of 5 articles: HTML format
Single Articles
September 2025
IMPERIALE TF In MASH with moderate or advanced liver fibrosis, weekly semaglutide improved
histologic steatohepatitis and fibrosis at 72 wk.
Ann Intern Med. 2025 Sep 2. doi: 10.7326/ANNALS-25-03308. PubMedAbstract available
January 2025
ALI SMJ, Lai M Metabolic Dysfunction-Associated Steatotic Liver Disease.
Ann Intern Med. 2025;178:ITC1-ITC16. PubMedAbstract available
October 2024
KORULA J In adults with metabolic dysfunction, the MAF-5 score predicted risk for liver
fibrosis (AUC range, 0.73 to 0.81).
Ann Intern Med. 2024;177:JC119. PubMedAbstract available
July 2024
SIMON TG, Singer DE, Zhang Y, Mastrorilli JM, et al Comparative Effectiveness and Safety of Apixaban, Rivaroxaban, and Warfarin in
Patients With Cirrhosis and Atrial Fibrillation : A Nationwide Cohort Study.
Ann Intern Med. 2024 Jul 9. doi: 10.7326/M23-3067. PubMedAbstract available
June 2024
MIRONOVA M, Sherker AH In NASH with liver fibrosis, resmetirom improved NASH resolution and reduced
fibrosis at 1 y.
Ann Intern Med. 2024;177:JC63. PubMedAbstract available